Vir Biotechnology shared important results from its Phase 3 trial, showing its treatment works well for chronic hepatitis delta.

Nov 9, 2026, 8:35 AM ETTrialRead the original at SEC EDGAR

Good for VIR

Vir reported positive Phase 3 results, with strong virus responses and few serious treatment problems. The smaller Phase 2 results also look encouraging, but stopping treatment was tested in only 10 patients, and the medicines remain under study.

VIR · Vir Biotechnology, Inc.

AI read · Good for VIR

The AI's read

These results suggest the treatment may help people with chronic hepatitis delta, including some with cirrhosis. The Phase 2 findings also show lasting virus suppression in patients who stopped treatment, but that test involved only 10 patients and remains exploratory. The medicines are still under study, so the results do not establish that they will be approved or sold.

Get alerts for VIR

Follow Vir Biotechnology, Inc. (VIR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for VIR

Free on the App Store and Google Play, or on the web.